Global outlook for eCTD 4.0 adoption: Successes and challenges
Key learnings
- Findings and lessons learned from the second phase of the EMA’s eCTD 4.0 EU technical pilot, and expectations for the coming months.
- Current state of eCTD 4.0 submissions to the FDA, exploring the synergies between US and EU applications.
- Important considerations for companies looking to adopt eCTD 4.0, including how it fits into your overall workflow of creating submissions, handling of the controlled vocabularies, keywords, and other eCTD 4.0 features.
- How forward compatibility works with the lifecycle of an existing eCTD dossier.
- Potential applications of eCTD 4.0 capabilities to the submission of structured product data in the future.
Access the recording
Connect with our team
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.
